Company: IPHYF
Filing Date: 2025-04-30
Form Type: 20-F
Source: 0001598599-25-000042
Chunk: 109

Company: Innate Pharma SA
Filing Date: 2025-04-30
Form: 20-F
Item: Item 4
Chunk 109
---
valumab plus monalizumab over durvalumab alone (36% vs. 18%). Data are published in the Journal of Clinical Oncology in 2022 (figure below).

At ASCO 2024, AstraZeneca presented an update on the trial results. After a median follow-up of 30.1 months, the findings showed a 12-month progression-free survival rate of 73.2% for durvalumab plus monalizumab, compared to 37.6% for durvalumab alone. The results also demonstrated an increase in the primary endpoint, confirmed overall response rate, for durvalumab plus monalizumab versus durvalumab alone (40.3% vs. 23.9%).

iii. Lung Cancer: Phase 2 NeoCOAST Study

In March 2022, the Phase 2 NeoCOAST multi-drug platform study assessing the safety and efficacy of neoadjuvant durvalumab in combination with chemotherapy and oleclumab, monalizumab or danvatirsen and adjuvant treatment in participants with resectable, early-stage non-small cell lung cancer was accepted for an oral presentation on April 11, 2022 at the Annual Meeting 2022 of the American Association for Cancer Research (AACR).” The study demonstrated that a single cycle of neoadjuvant durvalumab combined with oleclumab, monalizumab, or danvatirsen produced numerically improved MPR rates (19, 30 and 31.2%, respectively) compared with durvalumab alone (11.1%). No differences in pCR rates were observed between treatment arms.

iv. Lung Cancer: Phase 3 PACIFIC-9

In June 2023, AstraZeneca presented at the ASCO conference a trial-in-progress poster on the PACIFIC-9 study: "Phase 3 study of durvalumab combined with oleclumab or monalizumab in patients with unresectable stage III NSCLC (PACIFIC-9)."

PACIFIC-9 started in February 2022 and continues to enroll patients.

In 2024, the Independent Data Monitoring Committee recommended the continuation of the Phase 3 PACIFIC-9 trial based on a pre-planned analysis.

v. Lung Cancer: Phase 2 NeoCOAST-2

In June 2023, AstraZeneca presented at